DNA methylation of ANKK1 and response to aripiprazole in patients with acute schizophrenia: A preliminary study.
暂无分享,去创建一个
K. Iwamoto | Hiroshi Hoshino | H. Yabe | Y. Kunii | M. Hino | I. Miura | Junya Matsumoto | Keiko Kanno-Nozaki | S. Horikoshi | M. Bundo | H. Kaneko | Yasuto Kunii | Keiko Kanno‐Nozaki
[1] H. Yabe,et al. Associations between five-factor model of the Positive and Negative Syndrome Scale and plasma levels of monoamine metabolite in patients with schizophrenia , 2015, Psychiatry Research.
[2] H. Yabe,et al. Influence of −141C Ins/Del Polymorphism in DRD2 Gene on Clinical Symptoms and Plasma Homovanillic Acid Levels in the Treatment of Schizophrenia With Aripiprazole , 2015, Journal of clinical psychopharmacology.
[3] A. Kakita,et al. Elevated postmortem striatal t-DARPP expression in schizophrenia and associations with DRD2/ANKK1 polymorphism , 2014, Progress in Neuro-Psychopharmacology and Biological Psychiatry.
[4] G. Reynolds,et al. Methylation at a transcription factor-binding site on the 5-HT1A receptor gene correlates with negative symptom treatment response in first episode schizophrenia. , 2014, The international journal of neuropsychopharmacology.
[5] G. Reynolds,et al. Pharmacogenomics in psychiatry: the relevance of receptor and transporter polymorphisms. , 2014, British journal of clinical pharmacology.
[6] K. Kasai,et al. Comprehensive DNA methylation analysis of human neuroblastoma cells treated with blonanserin , 2014, Neuroscience Letters.
[7] V. Corces,et al. CTCF: an architectural protein bridging genome topology and function , 2014, Nature Reviews Genetics.
[8] K. Kasai,et al. DNA methylation in schizophrenia: progress and challenges of epigenetic studies , 2012, Genome Medicine.
[9] T. Lencz,et al. Pharmacogenetics in psychiatry: translating research into clinical practice , 2012, Molecular Psychiatry.
[10] S. Niwa,et al. Effects of Aripiprazole and the Taq1A Polymorphism in the Dopamine D2 Receptor Gene on the Clinical Response and Plasma Monoamine Metabolites Level During the Acute Phase of Schizophrenia , 2012, Journal of clinical psychopharmacology.
[11] Norio Sugawara,et al. Comparing the Influence of Dopamine D2 Polymorphisms and Plasma Drug Concentrations on the Clinical Response to Risperidone , 2011, Journal of clinical psychopharmacology.
[12] Felix Krueger,et al. Bismark: a flexible aligner and methylation caller for Bisulfite-Seq applications , 2011, Bioinform..
[13] A. Malhotra,et al. D2 receptor genetic variation and clinical response to antipsychotic drug treatment: a meta-analysis. , 2010, The American journal of psychiatry.
[14] R. Yoshimura,et al. Different patterns of longitudinal changes in plasma levels of catecholamine metabolites and brain-derived neurotrophic factor after administration of atypical antipsychotics in first episode untreated schizophrenic patients , 2010, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry.
[15] Yu-jung Chen,et al. Effects of DRD2/ANKK1 gene variations and clinical factors on aripiprazole efficacy in schizophrenic patients. , 2009, Journal of psychiatric research.
[16] J. Kwon,et al. Taq1A polymorphism in the dopamine D2 receptor gene as a predictor of clinical response to aripiprazole , 2008, European Neuropsychopharmacology.
[17] Adrian Bird,et al. Perceptions of epigenetics , 2007, Nature.
[18] A. Malhotra,et al. DRD2 promoter region variation as a predictor of sustained response to antipsychotic medication in first-episode schizophrenia patients. , 2006, The American journal of psychiatry.
[19] M. Neville,et al. Identification and characterization of ANKK1: A novel kinase gene closely linked to DRD2 on chromosome band 11q23.1 , 2004, Human mutation.
[20] M. Nöthen,et al. Polymorphisms in the dopamine D2 receptor gene and their relationships to striatal dopamine receptor density of healthy volunteers , 1999, Molecular Psychiatry.
[21] H. Arai,et al. First-episode neuroleptic-free schizophrenics: Concentrations of monoamines and their metabolites in plasma and their correlations with clinical responses to haloperidol treatment , 1997, Biological Psychiatry.
[22] J. Mill,et al. Epigenetic studies of schizophrenia: progress, predicaments, and promises for the future. , 2013, Schizophrenia bulletin.